JPMorgan Chase & Co. Raises Spire Healthcare Group (LON:SPI) Price Target to GBX 280

Spire Healthcare Group (LON:SPI) had its price target raised by analysts at JPMorgan Chase & Co. from GBX 249 ($3.12) to GBX 280 ($3.50) in a research report issued to clients and investors on Friday, Digital Look reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 27.43% from the company’s previous close.

Separately, Barclays increased their target price on shares of Spire Healthcare Group from GBX 300 ($3.75) to GBX 305 ($3.82) and gave the company an “overweight” rating in a research report on Friday.

Spire Healthcare Group Stock Performance

LON SPI opened at GBX 219.73 ($2.75) on Friday. The company has a market capitalization of £887.95 million, a price-to-earnings ratio of 10,986.25, a PEG ratio of 1.06 and a beta of 1.15. The company has a quick ratio of 0.74, a current ratio of 0.78 and a debt-to-equity ratio of 164.23. Spire Healthcare Group has a twelve month low of GBX 202 ($2.53) and a twelve month high of GBX 252.50 ($3.16). The stock has a fifty day simple moving average of GBX 216.20 and a 200 day simple moving average of GBX 220.31.

About Spire Healthcare Group

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.